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Abstract
Background: The analysis of cerebrospinal fluid (CSF) is usually done under steady-state conditions, when proteins
(e.g., immunoglobulins) reach diffusion equilibrium between blood and CSF. However, little data has been published
on CSF analysis under non-steady-state conditions after therapeutic apheresis. By reducing serum proteins (e.g.,
immunoglobulins), while leaving CSF unchanged, therapeutic apheresis might cause spuriously altered intrathecal
immunoglobulin fractions.
Methods: Based on the incidental finding of plasma exchange-induced increased intrathecal immunoglobulin
fractions in a cohort of 12 unsystematically selected patients with various neurological disorders, we retrospectively
investigated CSF results that had been raised during routine diagnostic work-up from 41 consecutive neurological
patients (predominantly Guillain-Barré syndrome and autoimmune encephalitis) treated with plasmapheresis or
immunoadsorption in a tertiary care university hospital in whom lumbar puncture (LP) was performed after a varying
number of treatments of therapeutic apheresis.
Results: Only when LP was performed 1 day after therapeutic apheresis, spurious quantitative intrathecal
immunoglobulin (Ig) synthesis of at least one subclass (IgG, IgA and/or IgM) was found in 68.4 % of the patients,
irrespective of the number of treatments, in all age groups and independent of other previous immunotherapies
(e.g., steroids). This phenomenon occurred only transiently and was almost always accompanied by an elevation
of the IgG index. In one patient, an elevated IgG index was noticed even 2 days after plasmapheresis. Neither
quantitative Ig synthesis, nor elevated IgG index was observed when the LP was performed three or more days
after therapeutic apheresis.
Conclusions: Spurious quantitative intrathecal Ig synthesis and increased IgG index are common findings shortly
after plasmapheresis or immunoadsorption due to altered serum immunoglobulin levels. Knowledge of this
phenomenon is needed for clinicians to prevent false interpretations leading to unnecessary diagnostic and
therapeutic procedures. Misdiagnoses can be avoided by considering the characteristic CSF constellation including
absence of oligoclonal bands and the close temporal relation to therapeutic apheresis.
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Background
The selective and dynamic function of the blood-
cerebrospinal fluid (CSF) barrier and the diffusion of
blood-derived proteins (for example, immunoglobulins)
into CSF has been described by Reiber et al. [1, 2]. The
results of simultaneous measurements of blood-derived
proteins in CSF and serum are usually expressed quantita-
tively as a CSF/serum quotient (e.g., immunoglobulin G
quotient QIgG). In some inflammatory neurological disor-
ders of infectious or autoimmune origin (e.g., neuroborre-
liosis, other viral and bacterial infections, and multiple
sclerosis), the disturbance of immunoglobulin (Ig) and al-
bumin quotients leads to an increase of the quantitatively
calculated intrathecal Ig fractions indicative of an intra-
thecal antibody production by local B-cells. In this regard,
intrathecal Ig synthesis strongly suggests a neuroinflam-
matory process [3].
In various neuroimmunological disorders (e.g., Guillain-
Barré syndrome, autoimmune encephalitis), plasmapher-
esis (plasma exchange, PE) or immunoadsorption (IADS),
taken together as therapeutic apheresis, are the treatments
of choice [4]. CSF analysis plays a key role in the diagnosis
of these disorders and is usually performed before starting
treatment [5, 6]. Occasionally, during or shortly after
therapeutic apheresis, a follow-up CSF analysis becomes
necessary for various reasons (e.g., control of CSF cell
count or pathogenic antibodies) in clinical routine.
By a transient and isolated reduction of serum proteins,
while leaving CSF relatively unchanged, PE or IADS might
cause spuriously altered results in the quantitative CSF ana-
lysis. In particular, the relative CSF Ig fractions and the re-
spective IgG index are expected to increase, based on the
current mathematical concepts used to describe CSF protein
composition and dynamics [3]. This could misleadingly sug-
gest an intrathecal antibody synthesis, and hence prompting
unnecessary extra diagnostics for search of an infectious or
another autoimmune disease (e.g., multiple sclerosis). Al-
though this phenomenon is acknowledged by CSF experts,
systematic data proving the existence of this “spurious quan-
titative intrathecal synthesis” are not available, and, to our
knowledge, there is to date only one case report describing
spurious intrathecal Ig synthesis after PE [7].
The objective of the present study was to retrospectively
determine intrathecal Ig fractions from patients with vari-
ous inflammatory neurological disorders (predominantly
Guillain-Barré syndrome, and autoimmune encephalitis),
and compare these before and after PE or IADS treatment
to estimate the influence of therapeutic apheresis.
Methods
Patients
Initially, an unsystematically selected cohort of 12 pa-
tients from the Department of Neurology at the Charité
University Medicine Berlin (Germany) receiving LP
immediately after treatment with PE between 2013 and
2014 (the Berlin study cohort) was investigated for the
occurrence of spurious quantitative intrathecal immuno-
globulin synthesis. To confirm the findings, we systematic-
ally investigated this phenomenon in a second, independent
patient cohort at the Department of Neurology at the
University Medical Center Freiburg, Germany (the Freiburg
study group). The following inclusion and exclusion criteria
were applied to avoid selection bias:
Inclusion criteria At the University Medical Center
Freiburg (Germany), electronic databases were screened
for neurological patients who were treated with either
plasmapheresis (PE) or immunoadsorption (IADS) be-
tween 2005 and 2014. Further inclusion criteria required
subjects to be aged ≥ 18 years and to have had at least
one LP (including a CSF and serum sample taken on the
same date) done within two months after PE or IADS.
Exclusion criteria We excluded all patients with neuro-
logical diseases (e.g., patients with multiple sclerosis or
autoimmune encephalitis), which commonly cause intra-
thecal Ig synthesis. Exceptions were patients with these
conditions who had no intrathecal Ig synthesis in a CSF
analysis before or more than 2 months after therapeutic
apheresis. Patients with hemolytic CSF samples were ex-
cluded from further analysis. Because our main focus in
further analyses was on intrathecal Ig fractions, we ex-
cluded patients with incomplete CSF and serum data,
particularly those lacking Ig analysis.
All patients gave written consent for LP during clinical
routine diagnostics. The ethics committee of the Univer-
sity Medical Center Freiburg approved the study.
Demographic and clinical data
Data regarding demographics (age, gender), neurological
diagnoses resulting in treatment with PE or IADS, dates
and number of treatments of therapeutic apheresis, and
other immunotherapies applied within 4 weeks before
these interventions were collected from electronic med-
ical records.
CSF analysis
In some patients LP was performed within, in others
after a complete apheresis cycle consisting of up to six
treatments. The methodology of CSF and serum analysis
was equivalent in both centers and according to the
German Society for Cerebrospinal Fluid Diagnostics
and Clinical Neurochemistry. The following routine la-
boratory CSF data were collected from medical records:
time interval between the last treatment of PE or IADS
and LP; total protein concentration; albumin concentra-
tion in CSF and serum; albumin quotient; immunoglobu-
lin (G, M, and A) concentrations in CSF and in serum;
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immunoglobulin (G, M, and A) quotients, as well as a
quantitative analysis of intrathecal immunoglobulin
(G, M, and A) fractions (IF; %) according to the for-
mula IgIF = [1-QLim(Ig)/QIg] × 100 [%] established by
Reiber et al. [2]; IgG index [8]; and finally, the pres-
ence of oligoclonal bands (OCBs) in CSF and in serum.
Concentrations of CSF and serum proteins were measured
nephelometrically (ProSpect System, Dade Behring, Sie-
mens, Germany) according to the manufacturer’s instruc-
tions. For detection of OCBs, CSF and serum samples
were diluted to IgG concentrations of 20 mg/l followed by
isoelectric focusing (IEF; Hydragel 9 CSF Isofocusing,
Sebia, France) and immunofixation. Intrathecal Ig synthe-
sis was considered significant if IF-values exceeded 10 %
in the quantitative analysis. An elevated IgG index was de-
fined as ≥ 0.65 and/or an increase of > 30 % compared to
values of an earlier LP. The term “spurious quantitative
intrathecal synthesis” is used in the context of this study if
elevated intrathecal immunoglobulin fractions or an in-
creased IgG index were caused by the non-steady-state
condition between serum and CSF occurring shortly after
therapeutic apheresis.
Statistical analysis
Because of the unsystematic patient selection of the Berlin
study cohort we did not pool data with the Freiburg study
group. The two-tailed Mann–Whitney U test was used for
statistical analyses comparing CSF results before and after
therapeutic apheresis within the Freiburg study group. A
p-value of < 0.05 was regarded as statistically significant.
Results
The Berlin study cohort
Of the 12 patients treated between 2013 and 2014, ten
were females, and two were males. The average age was
46 years (range 22–77 years). Eight patients were diag-
nosed with autoimmune encephalitis, two with neuro-
myelitis optica, one with multiple sclerosis, and one with
myelitis. In these 12 patients, between five and ten treat-
ments of PE were conducted. Six of the 12 patients had
an LP 1 day after PE that showed increased quantitative
intrathecal immunoglobulin fractions (one of all three
classes, two of IgG and IgA, and three of IgG), support-
ing the hypothesis of spurious intrathecal Ig synthesis.
By contrast, the remaining six patients who had an LP
more than 1 day after PE with a median time interval to
CSF analysis of 18.0 days (range 3–26 days) did not
demonstrate increased intrathecal immunoglobulin frac-
tions. Of the six patients with spurious intrathecal Ig
synthesis, one patient with autoimmune encephalitis and
IgG as well as IgA synthesis had persistence of an in-
creased IgA fraction in the further course, whereas the
other five (two with autoimmune encephalitis, two with
neuromyelitis optica, and one with myelitis) had a CSF
analysis before PE without increased intrathecal im-
munoglobulin fractions. In these six patients LP showing
increased intrathecal Ig fractions was performed after
a median number of three apheresis treatments (range
1–6 treatments).
The Freiburg study group
At University Medical Center Freiburg, 346 neurological
patients who were treated with either PE or IADS be-
tween 2005 and 2014 were identified. The vast majority
(234 cases) had to be excluded since no CSF analysis
had been performed within two months after therapeutic
apheresis; an additional 50 had incomplete CSF data (e.g.,
no serum taken). In addition, eight had neurological disor-
ders with intrinsic intrathecal Ig synthesis (e.g., multiple
sclerosis) and had no other CSF analysis showing the
absence of quantitative intrathecal Ig synthesis. In 13
patients, data on therapeutic apheresis were not avail-
able. Finally, 41 patients fulfilled all study criteria.
The mean age at the time of therapeutic apheresis was
58 years (range 24–80 years); gender distribution was
balanced (21 females and 20 males; Table 1). The major-
ity (63.4 %) was diagnosed with Guillain-Barré syndrome
(other diagnoses are listed in Table 1). Relevant routine
laboratory CSF results of all 41 patients who underwent
84 consecutive LPs are listed in Table 2. Thirty-four of
them had an additional LP before and nine had a further
follow-up LP. Thirty-seven patients were treated with
PE, and four were treated with IADS. In 19 patients
(46.3 %), LPs were performed 1 day after therapeutic
apheresis, with the number of treatments ranging be-
tween one and five. Thirteen patients (68.4 %) showed
elevated intrathecal Ig fractions with similar frequencies
for all three Ig subclasses (Fig. 1). Of these 13 patients
nine had Guillain-Barré syndrome and one chronic relaps-
ing inflammatory optic neuropathy (CRION), multiple
Table 1 Diagnoses of the 41 patients of the Freiburg study
group
Diagnosis
Guillain-Barré syndrome, n (%) 26 (63.4)
Autoimmune encephalitis, n (%) 6 (14.6)
Miller-Fisher syndrome, n (%) 2 (4.9)
Chronic relapsing inflammatory optic neuropathy
(CRION), n (%)
1 (2.4)
Multiple sclerosis, n (%) 1 (2.4)
Parainfectious myelitis, n (%) 1 (2.4)
Myasthenia gravis, n (%) 1 (2.4)
Anti-Yo-associated paraneoplastic cerebellar degeneration,
n (%)
1 (2.4)
Anti-Hu-associated polyneuropathy, n (%) 1 (2.4)
Neuromyelitis optica, n (%) 1 (2.4)
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sclerosis, paraneoplastic cerebellar degeneration and neu-
romyelitis optica each. A median number of four apheresis
treatments (range 1–5 treatments) were performed before
increased intrathecal Ig fractions were detected. Elevated
intrathecal Ig fractions were seen in 12 of 37 patients
treated with PE and in one of four patients after IADS. In
10 of the 13 patients with increased intrathecal immuno-
globulin fractions 1 day after therapeutic apheresis, data
from an additional CSF analysis before or during further
follow-up, showed no increased fractions. In two patients
we had both, showing disappearance of the elevated im-
munoglobulin fractions during the further course. In
one patient with Guillain-Barré syndrome and increased
fractions 1 day after PE we had no data of follow-up CSF
analysis. Table 3 showing CSF and serum data of a repre-
sentative patient before and 1 day after PE, demonstrates
that reduced serum Ig levels were accompanied by hardly
altered CSF results, therefore leading to an increase of
the respective quotients and intrathecal immunoglobu-
lin fractions.
Elevated intrathecal immunoglobulin fractions were seen
after one or more treatments, in patients from all age
groups, independent of other previous immunotherapies
(data not shown), and in a variety of neurological diagnoses
(Table 1). Elevated intrathecal immunoglobulin fractions
were always accompanied by an increased IgG index
(Fig. 2). Five of the six patients on whom LPs were per-
formed 1 day after therapeutic apheresis, but who had no
elevated intrathecal Ig fractions, demonstrated an elevated
IgG index (data not shown). According to quantitative IF
analysis (data not shown), none of the 22 patients who
underwent LP more than 1 day after therapeutic apheresis
Table 2 CSF parameters of 41 patients undergoing therapeutic apheresis (Freiburg study group)
CSF analysis
Prior to treatment One day after treatment Two days after treatment More than two days after treatment
(median 14.0 days; range 3–55; SD 13.5)
n (%) 33 (80.5) 19 (46.3) 4 (9.8) 18 (43.9)
Intrathecal IgG synthesis, n (%) 0 (0.0) 9 (47.4) 0 (0.0) 0 (0.0)
Intrathecal IgA synthesis, n (%) 1 (3.1) 7 (36.8) 0 (0.0) 0 (0.0)
Intrathecal IgM synthesis, n (%) 1 (3.1) 8 (42.1) 0 (0.0) 0 (0.0)
IgG index≥ 0.65, n (%) 6 (18.8) 18 (94.7) 1 (25.0) 1 (5.6)
OCBs predominantly in CSF, n (%) 1 (3.1) 0 (0.0) 0 (0.0) 1 (5.6)
Abbreviations: CSF cerebrospinal fluid, IgG, IgA, and IgM immunoglobulins G, A, and M, OCBs oligoclonal bands, SD standard deviation
Fig. 1 Scatter plot showing the percentage of intrathecal
immunoglobulin fractions in patients from the Freiburg study group
of the IgG, IgA, and IgM class before (left three columns) and 1 day
after (right three columns) therapeutic apheresis. Only patients with
available, complete CSF and serum data before and 1 day after
therapeutic apheresis were included in this graph (n = 12). Each
triangle represents one patient; the line within the triangles of each
column represents the median. Intrathecal immunoglobulin fractions
were considered relevant if they exceeded 10 % (as indicated by the
dotted line). Abbreviations: IgG, IgA, and IgM= immunoglobulins G, A,
and M; IF = intrathecal fraction
Table 3 Results of CSF and serum analyses of a representative
study patient
CSF/serum biomarker [normal range] LP before PE LP one day
after PE
CSF total protein concentration (mg/L)
[<450]
451 820
CSF albumin (mg/L)/serum albumin (g/L)
[110-350/35-52]
276/41.9 471/53.2
QAlb [for age 50 years: < 7.3] 6.5 8.9
CSF IgG (mg/L)/serum IgG (g/L) [14-40/7-16] 26.9/9.79 16.7/2.23
QIgG 2.7 7.4
IgG synthesis (%) 0 8.6
IgG index 0.41 0.84




IgA synthesis (%) 0 29.2
CSF IgM (mg/L)/serum IgM (g/L) [<1/0.4–2.3] 0.63/1.34 0.75/0.19
QIgM 0.4 4.0
IgM synthesis (%) 0 40.2
Abbreviations: CSF cerebrospinal fluid, LP lumbar puncture, PE therapeutic
plasma exchange, QAlb albumin quotient, IgG, IgA, and IgM immunoglobulins
G, A, and M, QIgG IgG quotient, QIgA IgA quotient, QIgM IgM quotient
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showed elevated intrathecal Ig fractions. In one patient, an
elevated IgG index was noticed 2 days after PE, but in none
of the patients with a CSF analysis three or more days after
therapeutic apheresis (data not shown). Strikingly, positive
or predominant OCBs in CSF were detected in none of the
19 cases with elevated intrathecal Ig fractions or an ele-
vated IgG index up to 2 days after therapeutic apheresis.
Discussion
In this study, we describe spurious intrathecal immuno-
globulin (Ig) synthesis of all three subclasses (IgG, IgA
and IgM) occurring 1 day after therapeutic apheresis in
6 of 12 selected patients (50.0 %, the Berlin study cohort),
as well as in 13 of 19 patients (68.4 %) from a well-defined,
independent, confirmatory cohort of patients with various
neurological disorders (the Freiburg study group). Add-
itionally, 18 of these 19 patients (94.7 %) had spuriously
elevated IgG indexes. While being well-acknowledged
among CSF experts, to our knowledge this is the first sys-
tematic study on these spurious phenomena.
The relevance of our findings is further illustrated by
the fact that the misinterpretation of spurious intrathecal
Ig synthesis 1 day after therapeutic apheresis resulted in
further specific diagnostics and/or unnecessary treatments
in some of our patients. For example, one patient with bi-
lateral facial palsy due to Guillain-Barré syndrome re-
ceived plasmapheresis as an initial treatment. Since a
follow-up LP revealed elevated intrathecal IgM fractions
and an ambiguous result for Borrelia burgdorferi serology,
treatment with ceftriaxone was started. In another case,
elevated intrathecal fractions of all three Ig classes led to
an extensive search for infectious pathogens in spite of a
normal cell count in CSF analysis.
In our study cohorts spuriously elevated intrathecal Ig
fractions were commonly found after therapeutic apher-
esis only in those cases for which the time interval after
therapeutic intervention to CSF analysis did not exceed
1 day. As expected, this finding was not restricted to PE
but was also observed after IADS. Furthermore, elevated
intrathecal Ig fractions were noticed irrespective of the
patient’s age, number of treatments, and other previous
immunotherapies. This finding was observed in various
neurological disorders, including GBS, autoimmune en-
cephalitis, and multiple sclerosis. A noticeably increased
IgG index always accompanied spurious elevated intra-
thecal Ig fractions and was observed even until 2 days
after PE. Due to the “selectivity” of the blood–brain-bar-
rier (BBB) with respect to molecular size [2], one would
expect a predominant increase of the intrathecal IgM
fraction after therapeutic apheresis. Surprisingly, spurious
intrathecal Ig synthesis was found with equal frequency in
all Ig classes in this study, including IgG with the smallest
molecular size.
The assumption that this phenomenon is spurious is
supported by several facts: (1) The Freiburg study group
mainly consisted of patients with neurological diagnoses
typically not associated with intrinsic intrathecal Ig syn-
thesis or elevated IgG index (e.g., Guillain-Barré syn-
drome) [5]. In cases of diagnoses possibly associated
with intrinsic intrathecal Ig synthesis (e.g., multiple
sclerosis), these patients were included only if a quanti-
tative CSF analysis before, or long after, therapeutic
apheresis did not show intrathecal Ig synthesis. (2) We
usually found unaltered Ig CSF concentrations after thera-
peutic apheresis, while serum Ig concentrations were mostly
decreased within the first day after intervention, thereby
leading to a relative increase of the respective CSF/serum
quotients. A representative patient, whose data is shown in
Table 3, illustrates this. (3) Elevated intrathecal Ig fractions
and elevated IgG index occurred only transiently, i.e., no
more than 1 day after PE or IADS for intrathecal Ig fractions
and 2 days for IgG index, respectively, and disappeared in
the further course, indicating a “steady-state equilibrium” of
CSF and serum proteins over time (data not shown) [1]. (4)
Contrary to the IgG index or to the quantitative analysis of
intrathecal Ig fractions using serum/CSF quotients, OCBs
measured in Western blots provide qualitative and highly
sensitive evidence for intrathecal IgG synthesis and are not
susceptible to spurious alterations due to non-steady-state
serum/CSF conditions [9]. As stated above, OCBs were de-
tected in none of the 19 cases with elevated intrathecal Ig
fractions or with an elevated IgG index up to 2 days after
therapeutic apheresis.
To ensure correct interpretation, CSF and serum sam-
ples should be analyzed under steady-state conditions
Fig. 2 Box-and-whiskers plots showing the IgG index of all patients
from the Freiburg study group with available, complete CSF and
serum data before (baseline, left plot) and 1 day after (day 1, right
plot) therapeutic apheresis (n = 12). The box plot includes all values
from the first (25.0 %) to the third quartiles (75.0 %), while the band
inside the box corresponds to the median. The ends of the whiskers
represent the minimum and maximum values, respectively. The
two-tailed Mann–Whitney test showed a significant difference
between the IgG index after, as compared to before, therapeutic
apheresis (p = 0.0001). Abbreviation: IgG = immunoglobulins G
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allowing proteins (e.g., immunoglobulins) to reach a dif-
fusion equilibrium, since the Reibergrams commonly
used for CSF analysis were developed under steady-state
serum/CSF conditions [1, 2]. Hence, under non-steady-
state conditions (e.g., shortly after PE or IADS), a critical
interpretation of CSF results is necessary since a rapid
and predominant decrease of immunoglobulins in serum
leads to a transient “imbalance” between the two com-
partments [5].
A limitation of this study is its retrospective character
and the small sample size of only 41 systematically se-
lected patients in the Freiburg study group. Additionally,
we included both patient groups receiving plasmapher-
esis or immunoadsorption, which are different thera-
peutic measures [10]. Briefly, therapeutic plasmapheresis
removes and replaces the complete plasma, containing
among others immunoglobulins, immune complexes and
coagulation factors. By contrast, immunoadsorption exclu-
sively removes immunoglobulins and immune complexes
from the plasma by a special “absorber”. However, the
relevant “pathophysiologic principle” important for this
study, namely reducing serum immunoglobulin levels
while leaving CSF levels unchanged, is equivalent in
both.
Conclusions
Transiently elevated intrathecal Ig fractions and increased
IgG index (“spurious intrathecal immunoglobulin synthesis”),
both due to dropped serum Ig levels, are frequent phe-
nomena occurring in the first 2 days following thera-
peutic apheresis. To avoid unnecessary diagnostic and
therapeutic procedures, clinicians should be aware of this
spurious phenomenon. Recognition of “spurious intra-
thecal synthesis” is possible when taking into account the
absolute concentrations of CSF and serum Ig. In addition,
OCBs should be considered to distinguish between “real”
and “spurious” Ig synthesis, as they remain negative in the
CSF despite spuriously elevated intrathecal Ig fractions
and/or IgG indexes. If CSF analysis of intrathecal Ig
synthesis is indicated after therapeutic apheresis, we
recommend a minimum time interval of 3 days between
apheresis and LP.
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